ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.380
$0.005 (1.30%)
Day Range
$0.380 - $0.395
52 Week Range
$0.120 - $0.630
Volume
45.00K
Avg Volume (10D)
303.31K
Market Cap
$96.50M
Price Chart
Market Statistics
Open$0.395
Previous Close$0.385
Day High$0.395
Day Low$0.380
52 Week High$0.630
52 Week Low$0.120
Valuation
Market Cap96.50M
Shares Outstanding253.96M
Price to Book14.29
Trading Activity
Volume45.00K
Value Traded17.24K
Bid$0.380 × 25,000
Ask$0.410 × 49,216
Performance
1 Day-1.30%
5 Day-15.56%
13 Week-18.28%
52 Week100.00%
YTD-11.63%
Technical Indicators
RSI (14)41.66
50-Day SMA$0.414
200-Day SMA$0.342
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read